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Outcomes in Patients With COVID-19 Disease and High
Oxygen Requirements
Geurys Rojas-Martea, b, Arsalan Talib Hashmia, Mazin Khalida, e, Nnamdi Chukwukac, Joshua Fogeld,
Alejandro Munoz-Martinezc, Samantha Ehrlichc, Maham Akbar Waheedc, Dikshya Sharmac,
Shaurya Sharmac, Awais Aslamc, Sabah Siddiquia, Chirag Agarwala, Yuri Malysheva,
Carlos Henriquez-Felipea, Jacob Shania

Abstract
Background: Approximately 19% of people infected with the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) progress to
severe or critical stages of the coronavirus disease 2019 (COVID-19)
with a mortality rate exceeding 50%. We aimed to examine the characteristics, mortality rates, intubation rate, and length of stay (LOS)
of patients hospitalized with COVID-19 disease with high oxygen requirements (critically ill).
Methods: We conducted a retrospective analysis in a single center
in Brooklyn, New York. Adult hospitalized patients with confirmed
COVID-19 disease and high oxygen requirements were included. We
performed multivariate logistic regression analyses for statistically
significant variables to reduce any confounding.
Results: A total of 398 patients were identified between March 19th
and April 25th, 2020 who met the inclusion criteria, of which 247
(62.1%) required intubation. The overall mortality rate in our study was
57.3% (n = 228). The mean hospital LOS was 19.1 ± 17.4 days. Patients
who survived to hospital discharge had a longer mean LOS compared
to those who died during hospitalization (25.4 ± 22.03 days versus10.7
± 1.74 days). In the multivariate analysis, increased age, intubation and
increased lactate dehydrogenase (LDH) were each independently associated with increased odds of mortality. Diarrhea was associated with
decreased mortality (OR 0.4; CI 0.16, 0.99). Obesity and use of vasopressors were each independently associated with increased intubation.
Conclusions: In patients with COVID-19 disease and high oxygen
requirements, advanced age, intubation, and higher LDH levels were
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associated with increased mortality, while diarrhea was associated
with decreased mortality. Gender, diabetes, and hypertension did not
have any association with mortality or length of hospital stay.
Keywords: COVID-19 disease; SARS-CoV-2; High oxygen requirement; Critically ill

Introduction
The coronavirus disease 2019 (COVID-19) is the most devastating pandemic of the 21st century. The first case was detected
in Wuhan, China in December 2019 [1]. Since then, the virus
has spread globally with an exponential increase in the number of cases. The causative organism, severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), is a single-stranded
ribonucleic acid (RNA) virus that belongs to the Coronaviridae family, and is transmitted mainly by respiratory droplets
[1, 2]. As of December 28th 2020, over 80 million cases have
been diagnosed worldwide with more than 13 million cases
in the USA [3]. Infection with SARS-CoV-2 ranges from an
asymptomatic carrier state to critical illness characterized by
acute respiratory distress syndrome (ARDS) with multi-organ
failure and death in the most severe cases [4].
Approximately 19% of people infected with the SARSCoV-2 virus progress to severe or critical COVID-19 disease
[4]. Critical illness is characterized by high oxygen requirements that ranges from oxygen supplementation via face mask
to intubation and mechanical ventilation. Risk factors associated with development of critical disease include older age,
hypertension, diabetes, and obesity [5]. Oxygen levels upon
admission and inflammatory markers, including C-reactive
protein (CRP) and lactate dehydrogenase (LDH) have been
proposed as predictors of poor prognosis in these patients [6].
Mortality in critically ill patients with COVID-19 is extremely high and exceeds 50% [4, 7]. Studies from the USA
have been limited by the inclusion of a large number of patients
who remain hospitalized at the time of the analysis [5, 8]. We
conducted a retrospective analysis to describe the characteristics,
mortality, intubation rate, and length of stay (LOS) of patients
hospitalized with COVID-19 disease and high oxygen requirement (critically ill) in a single center in Brooklyn, New York.
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Materials and Methods
Study setting
We conducted a single center, retrospective, observational
analysis at Maimonides Medical Center, a 711-bed tertiary
care teaching hospital in Brooklyn, New York. The Maimonides Medical Center Institutional Review Board approved the
study as minimal risk research and waived the need for informed consent. This study was conducted in compliance with
the ethical standards of the responsible institution on human
subjects as well as with the Helsinki Declaration.
We identified patients 18 years of age and older who were
admitted between March 19th and April 25th, 2020 with COVID-19 disease and high oxygen requirements. We considered
patients to have a high oxygen requirement if they developed
acute hypoxemic respiratory failure and required intubation with
mechanical ventilation or needed high-level oxygen supplementation (face mask at more than 10 L per minute, high-flow nasal
cannula (HFNC), or non-rebreather (NRB) oxygen face mask)
at the time of admission or during hospitalization. The accepted
method for diagnosing SARS-CoV-2 infection was real-time reverse transcription-polymerase chain reaction (RT-PCR) of a nasopharyngeal sample. All patients included in this study presented
to our emergency department with either symptoms suggestive of
COVID-19 infection or had a history of exposure to a person with
known COVID-19 infection. For patients who presented with
symptoms and had a positive result after being tested as outpatient, they were re-tested in our emergency department to confirm
COVID-19 infection. We excluded patients not requiring high
concentrations of oxygen, patients who died within 1 day of being
admitted, and those who died during their emergency room stay.

sults upon admission and the highest values recorded during
hospitalization (CRP, ferritin, D-dimer, LDH, troponin, and
procalcitonin), and complications including hemodialysis,
need for extracorporeal membrane oxygenation (ECMO), bacteremia, and/or fungemia, we developed prediction models for
intubation, length of hospital stay, and mortality.
Statistical analysis
Descriptive statistics of mean and standard deviation were used
to express continuous variables. Frequencies and percentages
were used to describe categorical variables. Skewed variables
were logarithmic-transformed. Troponin had values of 0, so 0.01
was added to all values and then the values underwent logarithmic transformation. For intubation, analysis of variance was
used to compare the continuous variables and the Pearson’s Chisquare test compared the categorical variables except for when
expected cell size was < 5 in which case Fisher’s exact test was
performed. Any variable that was statistically significant in the
univariate analysis was included in the multivariate logistic regression analysis. Univariate logistic regression was conducted
for the outcome variable of mortality. Any variable statistically
significant in the univariate analysis for mortality was included
in the multivariate analysis. Univariate linear regression was
conducted for the outcome variable of LOS. Any variable statistically significant in the univariate analysis for LOS was included in the multivariate analysis. All P values were two tailed.
Alpha level for significance was at P < 0.05. IBM SPSS Statistics Version 26 was used for all analyses (IBM, 2019).

Results
Baseline characteristics

Data collection

The primary outcome was in-hospital mortality. Mortality was
described as death in hospital following the diagnosis of COVID-19 disease. The secondary outcome was length of hospital
stay.

A total of 398 critically ill patients with COVID-19 disease
were included in this study. Two-hundred forty-seven (62.1%)
patients required intubation, and 151 (37.9%) needed oxygen
supplementation via HFNC or NRB oxygen mask. The mean
age was 65.8 years ± 16.26, and 52.8% of patients were 65
years or older. Two thirds of the patients (66.6%) were males,
while 19.1% Hispanic. Hypertension was the most common
comorbidity, (n = 237; 59.5%) followed by obesity (n = 167;
42.0%), and diabetes mellitus (n = 141; 35.4%). Other comorbidities included coronary artery disease (CAD) at 14.1%,
heart failure at 11.3%, atrial fibrillation at 9.8%, and chronic
obstructive pulmonary disease (COPD) at 6.8%. The most
common presenting symptoms included shortness of breath
(83.2%), fever (73.4%), and cough (70.9%). Patients’ demographics, comorbidities, presenting symptoms, and laboratory
values are given in Table 1. Additional baseline characteristics
are shown here (Supplementary Material 1, www.jocmr.org).

Prediction models

Management

Based on the clinical demographics, pertinent laboratory re-

Most patients received hydroxychloroquine (93.7%) and

Data were manually collected from the hospital’s electronic
medical record (Sunrise Clinical Manager). The information
collected included patients’ demographics, presenting symptoms, comorbidities, initial vital signs on admission, pertinent
laboratory tests, treatment received for COVID-19 disease,
need for vasopressor support, anticoagulation, use of antibiotics for suspected bacterial superinfection, and outcomes, including length of hospital stay, complications, and mortality.
Outcomes
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133 (33.4)

  Female sex

35 (8.8)
44 (11.1)
90 (22.6)

    Black

    Asian

    Other

7 (1.8)

    Unknown

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

27 (6.8)
22 (5.5)
56 (14.1)
36 (9.0)

   Chronic obstructive pulmonary disease

   Chronic kidney disease

   Coronary artery disease

  Dementia

292 (73.4)
282 (70.9)
74 (18.6)

  Fever

  Cough

  Myalgia

Presenting symptoms

45 (11.3)

141 (35.4)

  Diabetes mellitus

  Heart failure

237 (59.5)

  Hypertension
17 (4.3)

201 (50.5)

    Unknown

39 (9.8)

37 (9.3)

    Former

   Atrial fibrillation

7 (1.8)

    Active

  Cerebrovascular accident

153 (38.4)

    Never

  Smoking

  Obesity

167 (42.0)

76 (19.1)

    Hispanic

Comorbidities

315 (79.1)

    Non-Hispanic

  Ethnicity

229 (57.5)

    White

  Race

210 (52.8)

   Age (> 65 years)

24 (15.9)

105 (69.5)

104 (68.9)

21 (13.9)

21 (13.9)

10 (6.6)

15 (9.9)

15 (9.9)

15 (9.9)

8 (5.3)

47 (31.1)

88 (58.3)

82 (54.3)

10 (6.6)

2 (1.3)

57 (37.7)

48 (34.0)

5 (3.3)

26 (17.2)

120 (79.5)

35 (23.2)

20 (13.2)

14 (9.3)

82 (54.3)

55 (36.4)

78 (51.7)

67.5 (17.32)

Non-intubated (n = 151)

Whole sample (n = 398)
65.8 (16.26)

M (SD) or frequency (%)

M (SD) or frequency (%)

   Age (years) (mean)

Demographics

Variable

Table 1. Baseline Characteristics for the Study Population

50 (20.2)

177 (71.7)

188 (76.1)

15 (6.1)

35 (14.2)

12 (4.9)

12 (4.9)

30 (12.2)

24 (9.8)

9 (3.6)

94 (38.1)

149 (60.3)

119 (48.2)

27 (10.9)

5 (2.0)

96 (38.9)

119 (48.6)

2 (0.8)

50 (20.2)

195 (78.9)

55 (22.3)

24 (9.7)

21 (8.5)

147 (59.5)

78 (31.6)

132 (53.4)

64.8 (15.51)

Intubated (n = 247)

M (SD) or frequency (%)

0.28

0.65

0.11

0.01

0.94

0.46

0.052

0.49

0.95

0.43

0.16

0.69

0.42

0.01

0.16

0.66

0.32

0.73

0.11

P value
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331 (83.2)
37 (9.3)

   Shortness of breath

  Chest pain

27.1 (7.76)

   Respiratory rate (per minute)

748.6 (824.14)
51.1 (15.40)

   Lactate dehydrogenase (IU/L) (highest)

   Glomerular filtration rate
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4 (5.0)

1.9 (4.50)

1.4 (8.49)

48.7 (17.08)

575.7 (419.27)

3,368.2 (6,482.24)

1,239.2 (1,413.14)

18.6 (9.23)

1.5 (1.47)

137.3 (8.06)

227.5 (107.78)

12.9 (11.24)

8.8 (4.74)

24.6 (5.66)

88.1 (9.53)

98.0 (19.31)

15 (10.0)

124 (82.1)

25 (16.6)

44 (21.6)

9.2 (14.35)

1.2 (4.84)

52.5 (14.14)

848.9 (972.58)

9,692.1 (12,867.37)

1,815.5 (1,876.75)

28.5 (11.04)

1.4 (1.60)

134.8 (7.48)

202.8 (77.72)

11.8 (8.29)

8.8 (4.03)

28.6 (8.46)

86.2 (11.54)

103.6 (21.40)

22 (8.9)

207 (83.8)

33 (13.4)

23 (9.3)

Intubated (n = 247)

M (SD) or frequency (%)

0.001

< 0.001

< 0.001

0.02

< 0.001

< 0.001

0.001

< 0.001

0.92

0.002

0.01

0.81

0.88

< 0.001

0.09

0.01

0.72

0.66

0.38

0.66

P value

values are on admission unless otherwise specified. One patient was still hospitalized. Those with sample size for continuous variables less than 398 are: white blood cell
(n = 397), lymphocyte (n = 397), platelet (n = 397), creatinine (n = 396), C-reactive protein (n = 390), ferritin (n = 373), D-dimer (n = 217), lactate dehydrogenase (n = 373), glomerular
filtration rate (n = 391), troponin (n = 387), and procalcitonin (n = 350). Sample size for continuous variables less than 398 are: oxygen saturation (n = 396), respiratory rate (n = 391);
sample size for categorical variables missing are: obesity (n = 12), atrial fibrillation (n = 1), heart failure (n = 1), chronic obstructive pulmonary disease (n = 1), chronic kidney disease
(n = 1), nausea (n = 1), and chest pain (n = 1). M: mean; SD: standard deviation.

aLaboratory

48 (12.1)

7,564.7 (11,514.70)

   D-dimer (ng/mL) (highest)

   Aspartate transaminase (IU/L) (days 6 - 10) (> 120)

1,594.5 (1,734.71)

   Ferritin ng/mL (highest)

1.3 (6.43)

24.7 (11.44)

   C-reactive protein (mg/dL) (highest)

6.5 (12.25)

1.5 (1.55)

  Creatinine (mg/dL)

   Procalcitonin (ng/mL) (highest)

135.7 (7.79)

   Serum sodium (mmol/L)

   Troponin (ng/mL) (highest)

211.2 (90.93)

12.2 (9.52)

  Platelet

   Lymphocyte count (×

103/µL)

   White blood cell (× 103/µL)
8.8 (4.31)

86.9 (10.86)

  Oxygen saturation

Laboratory valuesa

101.5 (20.78)

   Heart rate (per minute)

Vital signs

58 (14.6)

  Diarrhea

16 (10.7)

Non-intubated (n = 151)

Whole sample (n = 398)
39 (9.8)

M (SD) or frequency (%)

M (SD) or frequency (%)

  Nausea

Variable

Table 1. Baseline Characteristics for the Study Population - (continued)
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azithromycin (93.2%). Tocilizumab was given to 29.6% of the
patients while 9.8% received remdesivir. Convalescent plasma
was given to 7.5% of patients, while 39.2% received full dose
anticoagulation. Table 2 summarizes the treatments received
during admission.
Complications
More than half of the patients (57.8%) needed vasopressor
support. Hemodialysis was used in one-fifth of patients while
blood transfusion was administered to 20.9%. Bacteremia and/
or fungemia were documented in one-fifth of the cases. The
majority of patients (91.5%) received antibiotics (Table 2).
Figure 1 shows the percentage of some of the complications
observed in the study population.
Predictors of intubation
Tables 1 and 2 show univariate comparisons for those patients
who were either intubated or nonintubated. In the multivariate analysis, only obesity and use of vasopressor were each
independently associated with increased odds for intubation
(Table 3).
Predictors of mortality
Overall mortality in our study was 57.3% (n = 228). In an
analysis comparing intubation and mortality, the mortality rate
was significantly higher in intubated patients (78.1%) as compared to those not intubated (23.2%). Table 4 shows logistic
regression analyses for mortality. In the multivariate analysis,
increased age, intubation, and increased LDH were each independently associated with increased odds of mortality. Diarrhea was independently associated with decreased mortality.
None of the comorbidities (including diabetes and hypertension), vital signs, treatment management, or complications
was significantly associated with mortality.
Predictors of LOS
The mean hospital LOS for the entire cohort was 19.1 ± 17.4
days. In the subset of patients who were discharged alive, mean
LOS was 25.4 ± 22.03 days. Patients who died during hospitalization had a mean LOS of 10.7 ± 1.74 days. In an analysis
comparing intubation and LOS, intubated patients had significantly greater mean LOS (21.7 ± 19.08 days) as compared to
those not intubated (14.8 ± 12.67 days) as shown in Table 2.
Table 5 shows the linear regression analyses for LOS. In
the multivariate analysis, Asian race, hemodialysis, ECMO
support, blood transfusion, treatment with steroids, remdesivir, or vitamin C, and diagnosis of bacteremia and/or fungemia
were each independently associated with increased LOS. CAD
was significantly associated with decreased LOS. In a multivariate analysis in the subset of patients who survived to dis30
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charge for variables significant in the whole sample multivariate analysis, hemodialysis, blood transfusion, use of vitamin C,
and diagnosis of bacteremia/fungemia were each significantly
associated with increased LOS. In the subset of patients with
mortality for those variables significant in the whole sample
multivariate analysis, blood transfusion, treatment with steroids, remdesivir, or vitamin C were each significantly associated with increased LOS. CAD was significantly associated
with decreased LOS.

Discussion
Our study represents one of the largest analyses of patients
with COVID-19 disease with high oxygen requirements and
complete outcomes. We included 398 critically ill patients, of
which 247 (62.1%) were intubated. The reported percentage of
intubation in COVID-19 patients with critical disease ranges
from 57% to 88% [7, 9-12]. We found obesity and use of vasopressors were each independently associated with higher
odds of intubation. These findings are consistent with a study
that reported higher rates of intubation in obese COVID-19
patients [10].
The mean LOS in our study population was 19.1 days. Other studies on critically patients with COVID-19 have reported
a LOS of 15 - 22 days [5, 10]. We found that patients who died
had a 2.5-time shorter LOS as compared to those who lived.
This finding is consistent with other studies that have reported
LOS for patients who died between 4 and 21 days and 4 to 53
days for those who were discharged alive [13].
The overall mortality in our cohort was 57.3%. This finding was mainly driven by a significantly higher mortality in
intubated patients than non-intubated patients (78.1% versus
23.2%). In a previous study addressing patients with COVID-19, we reported a mortality of 50%; however, that study
included patients with less severe disease [14]. Our current
findings are consistent with reports from China concerning
critically ill patients with COVID-19 disease. A study that
examined 239 critically ill patients, of which 69% were intubated, showed a 61.5% mortality [7]. Similarly, another group
reported a mortality rate of 56% in which more than half of
the studied patients were intubated [9]. In a study from Italy
that included 1,300 patients with COVID-19 treated in the intensive care unit (ICU), mortality was 26% despite 88% of the
patients being intubated. However, more than 50% of patients
remained hospitalized at the time of the analysis [15].
Studies from the New York City area have included cohorts of similar illness severity as our sample. The mortality
rate reported in these studies ranged from 39% to 68%. However, they included a high percentage of patients (ranging from
23% to 37%) who remained hospitalized at the time of the
analysis, which makes their results on mortality and LOS inconclusive [8, 11, 16]. In our study, only one patient remained
hospitalized under hospice care.
Various authors examined predictors of mortality and many
reported older age to be independently associated with increased
mortality [7, 11]. Other factors associated with higher mortality
in critically ill patients with COVID-19 include chronic cardiac
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150 (37.7)
247 (62.1)

  Intubation

80 (20.1)
4 (1.0)
83 (20.9)
373 (93.7)
371 (93.2)
153 (38.4)
309 (77.6)
156 (39.2)
30 (7.5)
39 (9.8)
252 (63.3)
213 (53.5)
118 (29.6)
364 (91.5)

  Hemodialysis

  ECMO support

  Blood transfusion

  Hydroxychloroquine

  Azithromycin

  Steroids

  Prophylactic anticoagulation

   Therapeutic anticoagulation

  Convalescent plasma

  Remdesivir

   Vitamin C

  Zinc

  Tocilizumab

   Antibiotics for suspected bacterial infection

18 (4.5)
11 (2.8)

   Deep vein thrombosis/pulmonary embolism

  Cerebrovascular accident
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10.7 (1.74)
25.4 (22.03)

   Length of stay (days) for patients who died

   Length of stay for patients who did not die

-

-

14.8 (12.67)

35 (23.2)

4 (2.8)

6 (4.0)

8 (5.3)

120 (80.0)

41 (27.2)

63 (43.2)

85 (58.2)

0 (0.0)

10 (6.8)

47 (31.3)

124 (84.4)

31 (20.7)

138 (92.0)

137 (91.3)

8 (5.3)

0 (0.0)

5 (3.3)

11 (7.3)

0 (0.0)

150 (37.7)

1 (0.25)

M (SD) or frequency (%)
Non-intubated (n = 151)

-

-

21.7 (19.08)

193 (78.1)

7 (2.9)

12 (4.9)

75 (30.5)

244 (98.8)

77 (31.2)

150 (60.7)

167 (67.6)

39 (15.8)

20 (8.2)

109 (44.3)

185 (75.8)

122 (49.4)

233 (94.3)

236 (95.9)

75 (30.6)

4 (1.6)

75 (30.4)

219 (88.7)

247 (100.0)

M (SD) or frequency (%)
Intubated (n = 247)

-

-

< 0.001

< 0.001

1.00

0.68

< 0.001

< 0.001

0.39

0.001

0.06

< 0.001

0.62

0.01

0.045

< 0.001

0.36

0.06

< 0.001

0.30

< 0.001

< 0.001

-

P value

mask higher than 10 L/min.
nasal cannula (HFNC)/non-rebreather oxygen mask (NRB mask). One patient was still hospitalized. Those with sample size for categorical
variables missing are: vasopressor (n = 1), need for hemodialysis (n = 1), need for ECMO support (n = 1), need for blood transfusion (n = 3), hydroxychloroquine (n = 2), azithromycin (n
= 1), steroids (n = 1), prophylactic anticoagulation (n = 7), therapeutic anticoagulation (n = 2), convalescent plasma (n = 6), remdesivir (n = 1), vitamin C (n = 5), zinc (n = 5), antibiotics
for suspected bacterial infection (n = 1), diagnosis of deep vein thrombosis/pulmonary embolism (n = 3), diagnosis of cerebrovascular accident (n = 8), and diagnosis of bacteremia/
fungemia (n = 1). Comparison between non-intubation and intubation groups reports percentages only for cases analyzed and does not include missing cases. Prophylactic anticoagulation included enoxaparin 40 mg (n = 58, 14.6%) enoxaparin 60 mg (n = 123, 30.9%), heparin (n = 74, 18.6%), and low-dose apixaban (n = 54, 13.6%). Therapeutic anticoagulation
included enoxaparin (n = 64, 16.1%), heparin drip (n = 18, 4.5%), DOAC (n = 71, 17.8%), and coumadin (n = 3, 0.8%). M: mean; SD: standard deviation; DOAC: direct oral anticoagulants; ECMO: extracorporeal membrane oxygenation.

bHigh-flow

19.1 (17.40)

   Overall length of stay (days) (mean)

aFace

228 (57.3)

  Mortality

Outcomes

83 (20.9)

  Bacteremia/fungemia

Complications

230 (57.8)

  Vasopressor

Treatment management

1 (0.25)

  HFNC/NRB maskb

M (SD) or frequency (%)
Whole sample (n = 398)

  Face maska

Oxygen requirement

Variable

Table 2. Management and Outcomes
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Table 3. Logistic Regression for Intubation
Variable

Multivariate, OR (95% CI)

Comorbidities
  Obesity

6.33 (1.45, 27.61)*

  Dementia

2.01 (0.20, 20.54)

Vital signs
   Heart rate (per minute)

1.01 (0.98, 1.04)

   Respiratory rate (per minute)

1.03 (0.92, 1.15)

Laboratory valuesa
   Platelet (× 103/µL)

1.09 (0.98, 1.21)

   Serum sodium (mmol/L)

0.99 (0.91, 1.07)

   C-reactive protein (mg/dL) (highest)

1.06 (0.99, 1.13)

   Ferritin (ng/mL) (highest)

0.21 (0.03, 1.27)

   Lactate dehydrogenase (IU/L) (highest)

15.40 (0.56, 427.25)

   Glomerular filtration rate

1.05 (0.99, 1.11)

   Troponin (ng/mL) (highest)

1.70 (0.72, 4.03)

Treatment management
  Vasopressor

92.25 (19.51, 436.28)***

  Hemodialysis

3.30 (0.34, 32.28)

  Blood transfusion

3.99 (0.37, 42.51)

  Steroids

2.31 (0.60, 8.94)

  Prophylactic anticoagulation

0.40 (0.05, 3.03)

   Therapeutic anticoagulation

0.26 (0.04, 1.53)

  Remdesivir

2.60 E8 (< 0.001, -)

  Zinc

0.93 (0.25, 3.44)

   Antibiotics for suspected bacterial infection

0.61 (0.08, 5.02)

Complications
   Diagnosis of bacteremia/fungemia

2.13 (0.31, 14.89)

*P < 0.05, ***P < 0.001. Analysis included one patient still hospitalized. Analysis includes 238 patients due to missing data. D-dimer, procalcitonin, and
aspartate transaminase were not included in the multivariate analysis due to a lot of missing data. Nagelkerke R Square = 0.82. aLaboratory values
are on admission unless otherwise indicated. OR: odds ratio; CI: confidence interval.

Figure 1. Complications in patients with COVID-19 disease and high oxygen requirements.
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Table 4. Mortality Analysis
Univariate

Multivariate

OR (95% CI)

OR (95% CI)

   Age (years)

1.04 (1.03, 1.06)***

1.07 (1.05, 1.10)***

  Female sex

0.90 (0.59, 1.38)

-

    White

1.00

1.00

    Black

1.20 (0.57, 2.53)

1.23 (0.39, 3.87)

    Asian

0.68 (0.36, 1.31)

1.06 (0.40, 2.83)

    Other

0.52 (0.32, 0.86)*

0.71 (0.32, 1.56)

  Hypertension

2.28 (1.51, 3.43)***

1.26 (0.65, 2.47)

  Heart failure

1.98 (1.01, 3.90)*

0.85 (0.31, 2.34)

0.56 (0.32, 0.97)*

0.40 (0.16, 0.99)*

1.05 (1.02, 1.08)**

1.03 (0.99, 1.07)

  Creatinine (mg/dL)

2.59 (1.14, 5.88)*

2.62 (0.65, 10.58)

   C-reactive protein (mg/dL) (highest)

1.05 (1.03, 1.07)***

1.02 (0.98, 1.05)

   Ferritin (ng/mL) (highest)

1.58 (1.003, 2.49)*

0.65 (0.28, 1.52)

   D-dimer (ng/mL) (highest)

1.98 (1.24, 3.15)**

-

   Lactate dehydrogenase (IU/L) (highest)

5.11 (1.98, 13.19)**

4.92 (0.999, 24.23)b

   Glomerular filtration rate

0.99 (0.98, 1.01)

-

   Troponin (ng/mL) (highest)

2.23 (1.61, 3.09)***

0.92 (0.58, 1.44)

   Procalcitonin (ng/mL) (highest)

1.72 (1.24, 2.40)**

-

   Aspartate transaminase (IU/L) (days 6 - 10) (> 120)

2.89 (1.41, 5.93)**

-

11.85 (7.30, 19.21)***

15.71 (5.48, 45.02)***

  Vasopressor

7.60 (4.84, 11.92)***

2.09 (0.76, 5.78)

  Hemodialysis

2.46 (1.43, 4.24)**

0.78 (0.35, 1.72)

   Antibiotics for suspected bacterial infection

4.03 (1.82, 8.91)**

0.80 (0.23, 2.84)

   Diagnosis of deep vein thrombosis/pulmonary embolism

0.58 (0.22, 1.50)

-

   Diagnosis of cerebrovascular accident

0.89 (0.27, 2.96)

-

   Diagnosis of bacteremia/fungemia

1.83 (1.10, 3.07)*

0.55 (0.26, 1.17)

Variable
Demographics

  Race

Comorbidities

Presenting symptoms
  Diarrhea
Vital signs
   Respiratory rate (per minute)
Laboratory

valuesa

Disease severity
  Intubation
Treatment management

Complications

aLaboratory

values are on admission unless otherwise indicated. bP = 0.05, *P < 0.05, **P < 0.01, ***P < 0.001. Analysis included one patient still
hospitalized. Multivariate analysis includes 333 patients due to missing data. D-dimer, procalcitonin, and aspartate transaminase were not included
in the multivariate analysis due to missing data. Nagelkerke R Square = 0.54. OR: odds ratio; CI: confidence interval. For brevity purposes, many
variables not statistically significant in the univariate analyses are not shown in the table.

disease (CAD and heart failure combined), high concentration
of interleukin-6, elevated D-dimer, thrombocytopenia, acute
kidney injury, and ARDS [7, 11, 17]. We found increased age,
LDH levels and intubation were each independently associated

with increased mortality. In a pooled analysis including 1,532
patients, LDH levels were found to be associated with a 16-fold
increase in mortality [18]. That analysis was based on the LDH
value upon admission, whereas in our study we used the highest
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< 0.001 (0.07)
0.07 (0.06)
0.12 (0.05)**

    Black

    Asian

    Other

0.13 (0.05)*
-0.05 (0.14)

    Hispanic

    Unknown

-0.12 (0.06)*
-0.17 (0.05)**

  Heart failure

   Coronary artery disease

0.01 (0.002)***
0.10 (0.04)*
0.12 (0.04)**
0.01 (0.001)***
0.08 (0.03)**
-0.13 (0.06)*

   C-reactive protein (mg/dL) (highest)

   Ferritin (ng/mL) (highest)

  D-dimer (highest)

   Glomerular filtration rate

   Procalcitonin (ng/mL) (highest)

   Alanine transaminase (IU/L) (days 6 - 10) (> 180)

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

0.11 (0.04)**
0.19 (0.05)***
0.85 (0.18)***
0.44 (0.04)***
0.29 (0.14)*

  Vasopressor

  Hemodialysis

  ECMO support

  Blood transfusion

  Ritonavir/lopinavir

Treatment management

  Intubation

0.12 (0.04)**

-0.28 (0.07)***

  Creatinine (mg/dL)

Disease severity

-0.01 (0.002)**

   Serum sodium (mmol/L)

Laboratory

-0.14 (0.06)*

   Atrial fibrillation

valuesa

-0.12 (0.04)**

  Hypertension

Comorbidities

Reference

    Non-Hispanic

Ethnicity

Reference

0.24 (0.16)

0.28 (0.05)***

0.36 (0.16)*

0.11 (0.05)*

-0.09 (0.06)

-0.03 (0.06)

-

-

-5.63 E-5 (0.002)

-

-0.02 (0.04)

0.001 (0.002)

-0.14 (0.14)

-0.001 (0.002)

-0.13 (0.05)*

0.03 (0.06)

-0.09 (0.06)

-0.03 (0.04)

-0.11 (0.13)

0.05 (0.05)

Reference

0.01 (0.05)

0.13 (0.06)*

0.02 (0.07)

Reference

-0.002 (0.01)

B (SE)

B (SE)
-0.01 (0.001)***

Multivariate

Univariate

    White

  Race

   Age (years) (mean)

Demographics

Variable

Table 5. Linear Regression for Length of Hospital Stay

-

0.25 (0.08)**

0.21 (0.18)

0.17 (0.08)*

-

-

-

-

-

-

-

-

-

-

-0.12 (0.08)

-

-

-

-

0.06 (0.06)

0.10 (0.07)

0.09 (0.10)

Reference

-

No mortality, B (SE)

Multivariate

-

0.23 (0.05)***

0.48 (0.29)

0.09 (0.05)

-

-

-

-

-

-

-

-

-

-

-0.19 (0.05)**

-

-

-

-

0.03 (0.05)

0.11 (0.07)

0.02 (0.07)

Reference

-

Yes mortality, B (SE)

Multivariate

Outcomes in COVID-19 and High O2 Requirements
J Clin Med Res. 2021;13(1):26-37

values are on admission unless otherwise indicated. *P < 0.05, **P < 0.01, ***P < 0.001. Analysis included one patient still hospitalized. Multivariate whole sample analysis
includes 338 patients due to missing data. Multivariate no mortality subsample includes 165 patients. Multivariate mortality subsample includes 225 patients. D-dimer, procalcitonin,
and alanine transaminase were not included in the multivariate analysis due to a lot of missing data. Multivariate whole sample adjusted R Square = 0.39. Multivariate no mortality
subsample adjusted R Square = 0.44. Multivariate mortality subsample adjusted R Square = 0.34. B: unstandardized beta; SE: standard error. For brevity purposes, many variables
not statistically significant in the univariate analyses are not shown in the table.

aLaboratory

0.09 (0.05)

-

0.12 (0.04)**

0.30 (0.08)***

0.19 (0.11)

0.28 (0.04)***
   Diagnosis of bacteremia/fungemia

   Diagnosis of cerebrovascular accident

0.25 (0.11)*

-

-

-

0.01 (0.04)

-

0.04 (0.04)

0.10 (0.04)*
  Tocilizumab

  Zinc

0.24 (0.04)***

-

0.12 (0.04)**

0.20 (0.06)**

0.08 (0.04)*

0.11 (0.05)*

0.16 (0.06)*

0.23 (0.04)***
   Vitamin C

  Remdesivir

0.24 (0.04)***

0.13 (0.09)

-

-

0.05 (0.07)

-

0.03 (0.04)

0.18 (0.07)*
  Convalescent plasma

   Therapeutic anticoagulation

0.12 (0.04)**

-

0.12 (0.04)**
0.11 (0.04)**
0.21 (0.04)***
  Steroids

B (SE)

0.07 (0.05)

Yes mortality, B (SE)

Multivariate

B (SE)

No mortality, B (SE)

J Clin Med Res. 2021;13(1):26-37

Univariate

Variable

Table 5. Linear Regression for Length of Hospital Stay - (continued)

Multivariate

Multivariate

Rojas-Marte et al

LDH value during hospitalization.
Even though diabetes mellitus and hypertension are recognized risk factors for developing severe COVID-19 disease,
they have failed to consistently show any association with
higher mortality in critically ill patients [17, 19, 20]. One study
found no difference in the rate of hypertension or diabetes between survivors and non-survivors of critical COVID-19 disease [7]. In contrast, another study reported a significant difference in mortality in patients with severe COVID-19 disease
with diabetes versus non-diabetic patients (81% versus 47%).
However, this difference in outcome could also be explained
by the 10-year difference in age between the groups in that
study [9]. Nonetheless, despite having a lower rate of hypertension and diabetes as compared to our cohort, both studies
reported similar number of intubated patients and mortality
rate similar to our findings [7, 9].
A study from Detroit, Michigan in the USA reported a
mortality rate of 39% in 141 patients with COVID-19 who
were treated in the ICU, including 114 (80%) intubated patients. Their cohort included 51.8% with diabetes and 78.7%
with hypertension and yet the reported mortality was significantly lower than other reports with COVID-19 patients of
similar severity [10]. These studies, including ours, suggest
that diabetes and hypertension might not affect mortality in
patients with COVID-19 disease once they progress to critical
illness. Similarly, we did not find any association between gender and mortality. This finding is consistent with previously
published data [7].
Previous studies examined gastrointestinal involvement
in COVID-19 and reported diarrhea to be associated with
prolonged symptoms, viral carriage, development of cytokine
storm, and multi-organ damage [21, 22]. Other researchers
have failed to establish an association between gastrointestinal symptoms, including diarrhea, with increased mortality,
LOS, or mechanical ventilation [23]. Our analysis showed
diarrhea to be independently associated with decreased mortality.
Limitations
Our study has some limitations. First, our analysis is subject to
data entry errors given that the information was manually collected. To minimize this, we performed multiple checks during the process of data collection. Prior to data analysis, we
double checked very abnormal laboratory values. Second, we
did not include mechanical ventilation settings, which could
be important information for management of these patients.
However, our objective was to focus on mortality and LOS
outcome. Third, smoking information was self-reported and
was not provided in over 50% of patients. This information
could be an important risk factor in patients with COVID-19
disease.
Conclusions
Our study shows a high mortality rate in COVID-19 patients
with high oxygen requirements. This finding is driven mainly
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by higher mortality in intubated patients. We found a significant difference in LOS between patients who died during hospitalization as compared to those who survived to discharge.
Older age, intubation, and higher LDH levels were associated
with increased mortality, while diarrhea was associated with
decreased mortality. Gender, diabetes, and hypertension did
not have any association with mortality or length of hospital
stay.
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